British Generic Manufacturers Association

From Wikipedia, the free encyclopedia

The British Generic Manufacturers Association is a trade association for the British generic drug industry. It has offices in the City of London.

Warwick Smith is the director general of the association and also of the .[1] Tim de Gavre, head of Sandoz UK is the chair from 2018.[2]

The association is concerned that a no-deal Brexit could force up the price of generic drugs because it would increase regulatory complexity.[3]

It is a member of the , a European organization dedicated to combatting antimicrobial resistance.[4]

It says it is working with the Department of Health and Social Care to deal with problems caused by generic drug shortages.[5]

In June 2019 it reported that the NHS was, on average, paying 193% of the manufacturers' selling price for Category M products, more than 500 medicines which are readily available with wholesalers receiving half of the profit and pharmacies receiving the other half.[6]

External links[]

References[]

  1. ^ "Proposals to include biologics in price controls could threaten NHS savings, says biosimilars head". Pharmaceutical Journal. 8 August 2018. Retrieved 4 November 2018.
  2. ^ "Tim de Gavre takes up BGMA Chair role". Pharma Times. 29 May 2018. Retrieved 4 November 2018.
  3. ^ "No-deal Brexit 'will force up price of generic drugs'". Health Service Journal. 26 September 2018. Retrieved 4 November 2018.
  4. ^ "Our Members". AMR Industry Alliance. 2017. Retrieved 4 November 2018.
  5. ^ "BGMA: WE ARE WORKING WITH DEPARTMENT OF HEALTH TO COUNTER GENERIC SHORTAGES". Pharmacy Biz. 29 October 2017. Retrieved 4 November 2018.
  6. ^ "NHS pays twice the price for generic medicines that manufacturers charge, finds report". Pharmaceutical Journal. 26 June 2019. Retrieved 23 August 2019.
Retrieved from ""